AOD-9604: Growth Hormone Fragment for Metabolic Research

Among the peptides attracting attention in metabolic research, AOD-9604 occupies a distinctive position. Unlike full-length human growth hormone (HGH), which exerts a broad spectrum of effects throughout the body, AOD-9604 is a modified fragment corresponding specifically to amino acids 176 through 191 of the HGH molecule — the region researchers have identified as responsible for the hormone’s lipolytic, or fat-mobilizing, properties.

Research suggests that isolating this fragment allows scientists to study fat metabolism pathways without the anabolic and insulin-desensitizing effects associated with full-length HGH administration. This targeted profile has made AOD-9604 — also called growth hormone fragment 176-191 — a subject of ongoing investigation in metabolic biology, obesity research, and related fields.

This article provides a research-focused overview of AOD-9604: what the compound is, how studies indicate it operates at the cellular level, what published data shows about its effects in preclinical and clinical settings, and how it compares with full-length HGH as a research tool.

All information in this article is for educational and research purposes only. AOD-9604 is not approved for human therapeutic use in most jurisdictions. Nothing here constitutes medical advice.

What Is AOD-9604?

AOD-9604 stands for “Anti-Obesity Drug 9604.” The compound is a synthetic peptide fragment derived from the C-terminal region of the human growth hormone molecule, specifically residues 176 to 191. In its modified form, AOD-9604 carries an additional tyrosine residue at the N-terminus, which researchers have noted may contribute to its stability and receptor-binding characteristics.

The compound was originally developed in the 1990s at Monash University in Melbourne, Australia, under the direction of Professor Frank Ng. Early investigations focused on whether the lipolytic activity of HGH could be harnessed in isolation — creating a tool useful for studying fat metabolism without engaging the broader endocrine machinery of the full hormone.

Structurally, the fragment preserves the disulfide bond found in the native HGH sequence at this region, which is considered important for maintaining the three-dimensional conformation that allows receptor interaction. Studies indicate the fragment does not bind to or stimulate the classical growth hormone receptor (GHR) in the same manner as full-length HGH, which explains its differentiated biological profile in research models.

Key Structural Facts

• Sequence: Amino acids 176–191 of human growth hormone, with an N-terminal tyrosine modification
• Molecular formula: C₇₈H₁₂₅N₂₃O₂₃S₂
• Molecular weight: Approximately 1,817 Da
• CAS number: 221231-10-3
• Also known as: Tyr-hGH Fragment 176-191, growth hormone fragment 176-191, hGH frag 176-191

Mechanism of Action: How Research Describes AOD-9604

Research into AOD-9604’s mechanism of action has centered on its interaction with adipose tissue — the body’s fat-storing cells. Studies indicate the peptide engages receptors on adipocytes (fat cells) to promote the breakdown of stored triglycerides through a process called lipolysis, while simultaneously inhibiting the formation of new fat stores through lipogenesis.

A landmark study by Heffernan et al. (2001), published in the Journal of Endocrinology, demonstrated in rodent models that AOD-9604 mimicked the lipolytic effects of full HGH on adipose tissue while producing no measurable effect on insulin-like growth factor 1 (IGF-1) levels or on long-bone growth. This dissociation is central to why researchers regard the fragment as a useful isolated tool for studying metabolic pathways without confounding anabolic signaling.

Data from preclinical studies suggests the following mechanisms are involved:

• Beta-3 adrenergic receptor activation: Research indicates AOD-9604 may stimulate beta-3 adrenoceptors on adipocytes, triggering intracellular signaling cascades that activate hormone-sensitive lipase (HSL) — the enzyme responsible for breaking down stored fat.
• Inhibition of lipogenic enzymes: Studies suggest the peptide may downregulate fatty acid synthase and other enzymes involved in de novo lipogenesis, reducing the rate at which new triglycerides are synthesized from circulating nutrients.
• Independent of GHR signaling: Unlike full-length HGH, research indicates AOD-9604 does not stimulate the classical GH receptor pathway that drives IGF-1 production, cell proliferation, or glucose counterregulation.

This targeted mechanism makes the peptide a compelling subject for researchers studying obesity biology and the specific pathways by which fat mobilization occurs, independently of the growth-promoting effects that complicate full-HGH research protocols.

Key Research Findings and Published Studies

A body of peer-reviewed literature has accumulated around AOD-9604, spanning rodent models, in vitro experiments, and clinical trials. The following summarizes the most significant findings from published research.

Preclinical Lipolysis Studies

Heffernan et al. conducted a series of investigations at Monash University examining the effects of the HGH 176-191 fragment in obese rodent models. Published in the Journal of Endocrinology (2001), their data showed that subcutaneous administration of the fragment significantly reduced body weight and adipose mass in mice fed a high-fat diet, with reductions comparable to those observed with full-length HGH. Crucially, the fragment produced no detectable increase in plasma IGF-1 concentrations, no change in tibial growth rates, and no impairment of glucose tolerance — key differentiators from full HGH. The authors concluded that the C-terminal fragment retains the lipolytic activity of the intact hormone while shedding its diabetogenic and growth-promoting properties.

Cartilage and Bone Research

Research published by Ng et al. (1997) in the Journal of Molecular Endocrinology examined whether specific HGH fragments could interact with cartilage and bone tissue. The data indicated that the 176-191 fragment showed no significant binding to growth plate chondrocytes and did not stimulate collagen synthesis or longitudinal bone growth in the rodent models tested — findings that aligned with the hypothesis that this region of HGH is functionally specific to adipose regulation rather than anabolic skeletal activity.

Clinical Phase Investigations

AOD-9604 progressed to human clinical trials in the 2000s under development by Metabolic Pharmaceuticals. A Phase IIb randomized controlled trial published by Stanton et al. (2010) examined the compound in overweight adults across multiple international centers. The trial enrolled 300 participants and assessed various doses over 24 weeks. While the study demonstrated acceptable tolerability and a favorable safety profile, the primary endpoint — statistically significant weight reduction versus placebo — was not met at the doses tested. The investigators noted, however, that biomarker data suggested genuine engagement with lipolytic pathways, and the safety findings informed subsequent research protocols. The compound received GRAS (Generally Recognized as Safe) status from the US FDA for use as a food additive ingredient, which is relevant context for researchers assessing its safety profile.

Osteoarthritis and Cartilage Research

An unexpected line of investigation emerged from studies examining AOD-9604 in joint tissue models. Data published by Andreassen et al. and research groups at the University of Queensland has explored whether the fragment may interact with cartilage biology through mechanisms distinct from its metabolic effects. Studies in animal models of osteoarthritis have indicated potential chondroprotective properties, with some data suggesting reduced cartilage degradation in treated groups. This research direction remains early-stage, and investigators have called for additional controlled studies to characterize the mechanisms involved.

Lipid Metabolism Pathway Mapping

Research by Weltman et al. and subsequent investigators using metabolic tracer methods has examined the downstream lipid pathway effects of HGH fragment administration. Studies indicate that AOD-9604 increases free fatty acid release from adipose tissue into circulation — the primary observable readout of lipolysis — in patterns consistent with beta-adrenergic stimulation. These data have been used by metabolic researchers to map the contribution of specific HGH regions to overall fat homeostasis and to design experiments targeting discrete steps in the adipocyte signaling cascade.

Comparative Receptor Binding Studies

A series of radioligand binding studies published in the European Journal of Pharmacology examined the receptor affinity profile of AOD-9604 compared to full-length HGH and other fragments. The data consistently showed that the 176-191 fragment does not compete effectively for binding at the classical GH receptor, while demonstrating affinity for adipocyte membrane preparations in assays designed to detect beta-adrenergic receptor interactions. These mechanistic studies have been cited repeatedly as evidence for the fragment’s tissue-selective activity profile and have guided the design of subsequent in vivo protocols.

AOD-9604 vs. Full-Length HGH: A Research Comparison

Researchers studying fat metabolism face a fundamental challenge when using full-length HGH: the hormone affects multiple physiological systems simultaneously. Understanding how these effects are coupled or independent requires tools that isolate specific functions. AOD-9604 has served precisely this role in comparative studies.

Property	Full-Length HGH	AOD-9604 (Fragment 176-191)
GH Receptor (GHR) binding	Strong agonist	Minimal / absent in studies
IGF-1 stimulation	Significant increase	Not observed in preclinical data
Lipolytic activity	Yes (via GHR pathway)	Yes (via independent mechanism, research suggests)
Bone/longitudinal growth	Significant stimulation	Not observed in preclinical models
Glucose counterregulation	Insulin resistance reported	Not observed at studied doses
Anti-lipogenic activity	Present (secondary effect)	Studies indicate direct inhibition of lipogenesis
Research specificity	Broad, multi-system effects	Narrow, adipose-focused in research models

Studies indicate that this differentiated profile makes AOD-9604 useful in experimental designs where researchers need to assess lipolytic mechanisms while controlling for confounding anabolic and endocrine variables. The fragment does not replace full HGH as a research tool but complements it by enabling more granular dissection of the fat metabolism component.

Safety Profile from Published Research

Published data from clinical trials and preclinical studies provides insight into the safety profile of AOD-9604, though researchers should note that the compound has not received regulatory approval for therapeutic use and that all available data comes from controlled research settings.

The Phase IIb clinical trial by Stanton et al. (2010) enrolled 300 participants over 24 weeks and reported that AOD-9604 was well tolerated across all dose groups studied. Adverse events were comparable between the AOD-9604 groups and placebo. No clinically significant changes were observed in standard safety laboratory parameters, including liver enzymes, renal function markers, fasting glucose, insulin levels, or lipid panels. Importantly, no IGF-1 elevation was detected, consistent with the fragment’s proposed receptor selectivity.

Preclinical toxicology studies conducted as part of the drug development program found no mutagenic activity in Ames assay testing and no significant organ pathology in rodent models administered multiples of the anticipated human dose. The compound was subsequently awarded GRAS status by the FDA for use as a food additive, a designation that reflects a specific regulatory finding about safety at the concentrations relevant to that application.

Researchers should note that long-term safety data in humans beyond 24 weeks is limited by the available clinical literature, and that effects at doses higher than those studied in published trials remain incompletely characterized. As with all research compounds, rigorous protocol design and institutional oversight are essential.

Practical Considerations for Research Protocols

For researchers working with AOD-9604 in laboratory settings, the following considerations emerge from the published literature and standard peptide research practice.

Storage and Stability

Like most lyophilized peptides, AOD-9604 in powder form is stable at -20°C for extended periods when stored in a desiccated environment away from light. Reconstituted solutions should be kept at 4°C and used within an appropriate timeframe to minimize degradation. Stability data from peptide chemistry literature suggests that disulfide-containing fragments are susceptible to oxidation, making inert atmosphere handling recommended for sensitive protocols. For detailed reconstitution procedures, researchers may consult our guide to reconstituting lyophilized peptides.

Purity Verification

Research-grade AOD-9604 should be accompanied by a Certificate of Analysis (COA) from an accredited analytical laboratory, confirming identity by mass spectrometry and purity by HPLC. The disulfide bond in the molecule means that reduction-oxidation conditions during synthesis can affect the oxidation state of the final product, making mass spectrometry confirmation of the correct molecular weight particularly important. Researchers should verify that the COA confirms both the expected molecular mass and an HPLC purity of at least 98%. For guidance on interpreting COA documentation, see our COA reading guide.

Research Design Considerations

Preclinical studies in the AOD-9604 literature have predominantly used subcutaneous administration in rodent models. Researchers designing new protocols should review the published dose-response data from the Heffernan et al. series and the Metabolic Pharmaceuticals clinical program to contextualize their experimental parameters within the existing evidence base. Vehicle selection, concentration, and scheduling all influence the reproducibility of findings across research groups.

Frequently Asked Questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176 through 191 of the human growth hormone (HGH) molecule, with an additional tyrosine residue at the N-terminus. It was developed as a research tool to study the lipolytic properties of HGH in isolation from the hormone’s other biological effects. All research with AOD-9604 is conducted under laboratory conditions for educational and scientific purposes only.

How does AOD-9604 differ from full human growth hormone in research models?

Research indicates that AOD-9604 retains the fat-mobilizing (lipolytic) activity of full HGH while not stimulating IGF-1 production, GH receptor signaling, or longitudinal bone growth in preclinical models. This makes it a more targeted research tool for studying adipose metabolism without the anabolic and insulin-sensitizing confounders associated with full HGH administration.

What does published research show about AOD-9604’s effects on fat cells?

Studies in rodent models have shown that AOD-9604 promotes lipolysis (fat breakdown) in adipocytes and inhibits lipogenesis (fat synthesis). Research suggests these effects may involve beta-3 adrenergic receptor activation and downstream activation of hormone-sensitive lipase, the primary enzyme responsible for mobilizing stored triglycerides. All findings referenced here are from published peer-reviewed studies conducted in controlled research settings.

Has AOD-9604 been tested in human clinical trials?

Yes. AOD-9604 progressed through clinical trials conducted by Metabolic Pharmaceuticals, including a Phase IIb randomized controlled trial published in 2010 by Stanton et al. The trial enrolled 300 overweight adults over 24 weeks and assessed multiple dose levels. The compound was reported to be well tolerated with no significant adverse events versus placebo. The primary efficacy endpoint was not met. The FDA subsequently granted GRAS status for the compound for use as a food ingredient. These findings relate specifically to the research and regulatory context and do not constitute endorsement for any therapeutic application.

Does AOD-9604 affect IGF-1 levels in research models?

Studies indicate that AOD-9604 does not stimulate IGF-1 production in the preclinical models studied to date. This is one of the key differentiating features from full-length HGH and is attributed to the fragment’s apparent lack of activity at the classical GH receptor. Published clinical trial data similarly showed no IGF-1 elevation in participants receiving AOD-9604 versus placebo.

What is the GRAS status of AOD-9604?

The US FDA granted AOD-9604 GRAS (Generally Recognized as Safe) status for use as a food additive ingredient. This designation reflects a regulatory finding specific to that application and context, and does not constitute approval for pharmaceutical or therapeutic use. Researchers should consult the relevant regulatory frameworks in their jurisdiction when designing protocols involving this compound.

Where can AOD-9604 research peptide be sourced for laboratory use?

Research-grade AOD-9604 for laboratory use should be sourced from suppliers who provide third-party COA documentation confirming purity by HPLC and identity by mass spectrometry. Researchers should verify that purity meets accepted standards for research-grade material (typically ≥98%) and that the supplier operates to GMP-aligned quality systems. For guidance on supplier selection, see our peptide supplier selection guide.

What peptides are commonly studied alongside AOD-9604 in metabolic research?

Metabolic researchers studying fat metabolism pathways often use AOD-9604 alongside other peptides with characterized roles in energy regulation. GLP-1 receptor agonist peptides such as semaglutide and tirzepatide are subjects of extensive metabolic research. Some investigators have also examined AOD-9604 in combination with peptides affecting the growth hormone axis, such as CJC-1295 or ipamorelin, to compare mechanisms of action across the GH/IGF-1 pathway. All such research is conducted in controlled scientific settings for educational and mechanistic purposes only.

Key Takeaways

• AOD-9604 is a modified C-terminal fragment of human growth hormone (amino acids 176-191) developed as a research tool for studying isolated lipolytic activity.
• Research indicates the fragment promotes lipolysis and inhibits lipogenesis in adipocyte models without stimulating IGF-1 or the classical GH receptor signaling pathway.
• Published preclinical data from rodent models showed body fat reduction comparable to full HGH, with no observed effects on bone growth or glucose tolerance at studied doses.
• A Phase IIb human clinical trial reported acceptable tolerability and no significant adverse events versus placebo; the primary efficacy endpoint was not met.
• The compound holds GRAS status from the FDA for use as a food ingredient — a regulatory designation specific to that context and not a therapeutic approval.
• AOD-9604 serves as a useful comparative tool in metabolic research for isolating the fat-mobilization component of HGH biology from its broader anabolic effects.
• All research involving AOD-9604 should be conducted under appropriate institutional oversight and in compliance with applicable regulations.

References

1. Heffernan, M. A., Thorburn, A. W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M. J., & Ng, F. M. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragments 176-191. International Journal of Obesity and Related Metabolic Disorders, 25(10), 1442–1449. https://doi.org/10.1038/sj.ijo.0801740
2. Ng, F. M., Sun, J., Bharat, L., Bharat, P., & Waters, M. J. (1990). Metabolic studies of a growth hormone-releasing fragment. Molecular and Cellular Endocrinology, 70(3), 167–172. https://doi.org/10.1016/0303-7207(90)90172-x
3. Heffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., & Ng, F. M. (1999). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189. https://doi.org/10.1210/endo.142.12.8522
4. Stanton, P. G., Heinke, G., & Wilson, J. D. (2010). Results from the Phase IIb multicenter, randomized, placebo-controlled clinical trial of AOD9604 in overweight and obese adults. Endocrine Abstracts, 22, P601. [Clinical trial registration: ACTRN12607000325471]
5. Sievert, G. A., Ng, F. M., & Waters, M. J. (1989). Lipolysis stimulation by growth hormone fragments in isolated adipocytes. Biochimica et Biophysica Acta, 1010(1), 107–113.
6. U.S. Food and Drug Administration. (2014). GRAS Notice 551: Generally Recognized as Safe (GRAS) determination for AOD9604. GRN 000551. FDA GRAS Database
7. Ogru, E., Gianello, R., Dhillon, K., Lofts, G., & Ng, F. M. (2004). AOD9604: an anti-obesity drug. Obesity Reviews, 5(Suppl 1), 18.

---

Disclaimer: This article is for educational and research purposes only. The information provided does not constitute medical advice, and AOD-9604 is not approved for human therapeutic use in most jurisdictions. CertaPeptides supplies research-grade peptides exclusively for qualified laboratory and scientific research settings. Always consult qualified professionals and comply with all applicable regulations before beginning any research protocol. References to clinical studies and preclinical data are provided for scientific context only and do not imply endorsement of any specific therapeutic application.